Clinical Reference Laboratory is to establish a European hub in the U.K. as part of a deal with Quotient Bioresearch through which the companies will jointly offer clinical laboratory and other specialist testing services to the global pharma, biopharma, and CRO industries.
CRL’s new European laboratory will be set up within Quotient Bioresearch’s existing facilities. The companies’ agreement will involve close collaboration to develop new services in areas like bioanalysis, biomarkers, and microbiology.
“The established capabilities of the two companies are entirely complementary,” comments David Griffiths Ph.D., Quotient’s business development director. “I anticipate synergies that will enable us to deliver a joint offering significantly broader than is available from each party working alone.”
Quotient specializes in early-stage drug development services and operates three business units: Quotient Radiochemistry and Metabolism, Quotient Bioanalytical Sciences (which includes microbiology), and Quotient Clinical. CRL offers testing services in the areas of clinical trials, corporate wellness programs, genomics, insurance, and toxicology.